Zacks Research Issues Pessimistic Outlook for PCRX Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Equities research analysts at Zacks Research lowered their Q1 2027 earnings per share estimates for Pacira BioSciences in a report released on Tuesday, April 22nd. Zacks Research analyst R. Department now anticipates that the company will earn $0.59 per share for the quarter, down from their prior estimate of $0.60. The consensus estimate for Pacira BioSciences' current full-year earnings is $2.41 per share. Zacks Research also issued estimates for Pacira BioSciences' FY2027 earnings at $2.63 EPS.

Several other research firms also recently issued reports on PCRX. Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 price objective on shares of Pacira BioSciences in a report on Tuesday, April 8th. Royal Bank of Canada reissued a "sector perform" rating and issued a $18.00 price objective on shares of Pacira BioSciences in a research report on Tuesday, January 14th. HC Wainwright upped their target price on shares of Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research note on Tuesday, April 8th. Barclays boosted their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. Finally, Truist Financial raised shares of Pacira BioSciences from a "sell" rating to a "hold" rating and raised their price objective for the stock from $8.00 to $25.00 in a report on Thursday, January 30th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Pacira BioSciences currently has an average rating of "Hold" and an average price target of $26.67.

Pacira BioSciences Stock Up 5.5 %

Shares of PCRX traded up $1.42 during trading hours on Friday, hitting $27.14. 1,447,866 shares of the company were exchanged, compared to its average volume of 982,678. The firm's 50 day moving average is $24.50 and its 200-day moving average is $21.53. Pacira BioSciences has a 52 week low of $11.16 and a 52 week high of $31.67. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The company has a market cap of $1.26 billion, a PE ratio of -13.37 and a beta of 0.71.

Hedge Funds Weigh In On Pacira BioSciences

A number of institutional investors have recently modified their holdings of PCRX. State of Wyoming increased its stake in shares of Pacira BioSciences by 8.0% in the 4th quarter. State of Wyoming now owns 6,566 shares of the company's stock valued at $124,000 after buying an additional 487 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Pacira BioSciences by 16.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock worth $68,000 after purchasing an additional 513 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Pacira BioSciences by 3.1% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company's stock worth $491,000 after purchasing an additional 794 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Pacira BioSciences by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock valued at $184,000 after purchasing an additional 918 shares during the last quarter. Finally, Sterling Capital Management LLC boosted its holdings in Pacira BioSciences by 779.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock worth $26,000 after buying an additional 1,208 shares during the last quarter. 99.73% of the stock is owned by institutional investors.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.